Stereotaxis Stock News

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -25% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis (NYSE:STXS) is scheduled to announce Q4 earnings results on Thursday, March 3rd, before market open.The consensus EPS Estimate is -$0.04 and the consensus Revenue Estimate…

ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, chairman and CEO, will present at three investor conferences in the first quarter 2022.

ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fis

ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r

"Stereotaxis reminds me in many ways of Intuitive Surgical in our early years." - Executive VP & CMO of Intuitive Surgical and new Stereotaxis board member. Innovation Day showcased significant cataly

Morgan Stanley boosted its holdings in shares of Stereotaxis, Inc. (NYSEAMERICAN:STXS) by 3,094.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 315,717 shares of the companys stock after acquiring an additional 305,835 shares during the quarter. Morgan Stanleys holdings in Stereotaxis were []

ST. LOUIS, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS ), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in Frontiers in Cardiovascular Medicine titled "Atrial Fibrillation Ablation Using Robotic Magnetic Navigation Reduces the Incidence of Silent Cerebral Embolism." This multi-center, prospective study evaluated 166 patients with paroxysmal or persistent Atrial Fibrillation (AF) who underwent pulmonary vein isolation using either Stereotaxis'' Robotic Magnetic Navigation (RMN) technology or manual contact force ablation catheters. All patients received cerebral magnetic resonance imaging within 48 hours before and after the ablation procedure to assess cerebral embolism. Patients treated using RMN had greater than 82% reduced incidence of silent cerebral embolism (SCE) at 5.77% compared to 32.26% in patients treated with manual catheter ablation (p<0.001). The study concluded, "ablation technology is the only independent risk factor of SCEs, and RMN can significantly reduce the incidence of SCEs resulting from AF ablation." This is the first study comparing incidence of SCEs following cardiac ablation with RMN compared to manual catheters and was performed independent of Stereotaxis in China by Wuxi People''s Hospital, Fuwai Hospital, Xuzhou Central Hospital, and the First Hospital Affiliated to Soochow University. "The results of this study further strengthen the significant safety and efficacy benefits we have experienced using robotic technology to treat over 600

Qurates most recent research report on AI-based Surgical Robots was performed by extremely qualified research professionals and business experts in order to provide an in-depth assessment on the market. The study on AI-based Surgical Robots is extensive and consist of

Zacks Investment Research cut shares of Stereotaxis (NYSEAMERICAN:STXS) from a hold rating to a strong sell rating in a report issued on Wednesday morning, Zacks.com reports. According to Zacks, Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospitals interventional surgical suite to enhance the treatment of coronary artery []

Related Stocks: COWN , GEF.B , STXS , WRK , LEN.B , CIT , JXN , SPNT , REVH , SPNT , NODK , KKR ,

Stereotaxis (NYSEAMERICAN:STXS) was downgraded by Zacks Investment Research from a hold rating to a strong sell rating in a report released on Wednesday, Zacks.com reports. According to Zacks, Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospitals interventional surgical suite to enhance the treatment of coronary artery disease []

ST. LOUIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it will host an inaugural Innovation Day by live webcast on December 13. The event will include presentations of the companys innovation pipeline by members of Stereotaxis leadership with a live Q&A session.

ST. LOUIS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces today that BJC HealthCare has become the first health care system in the midwest to offer the Genesis RMN system, advancing electrophysiology patient care and expanding access to advanced robotic technology for the treatment of cardiac arrhythmias in the greater St. Louis region.